334 related articles for article (PubMed ID: 34340250)
41. Vacuolization of hematopoietic precursors: an enigma with multiple etiologies.
Gurnari C; Pagliuca S; Durkin L; Terkawi L; Awada H; Kongkiatkamon S; Zawit M; Hsi ED; Carraway HE; Rogers HJ; Visconte V; Maciejewski JP
Blood; 2021 Jul; 137(26):3685-3689. PubMed ID: 33690844
[TBL] [Abstract][Full Text] [Related]
42. A clinical, histopathological, and molecular study of two cases of VEXAS syndrome without a definitive myeloid neoplasm.
Li P; Venkatachalam S; Ospina Cordona D; Wilson L; Kovacsovics T; Moser KA; Miles RR; Beck DB; George T; Tantravahi SK
Blood Adv; 2022 Jan; 6(2):405-409. PubMed ID: 34649277
[TBL] [Abstract][Full Text] [Related]
43. Somatic Mutations in UBA1 Define a Distinct Subset of Relapsing Polychondritis Patients With VEXAS.
Ferrada MA; Sikora KA; Luo Y; Wells KV; Patel B; Groarke EM; Ospina Cardona D; Rominger E; Hoffmann P; Le MT; Deng Z; Quinn KA; Rose E; Tsai WL; Wigerblad G; Goodspeed W; Jones A; Wilson L; Schnappauf O; Laird RS; Kim J; Allen C; Sirajuddin A; Chen M; Gadina M; Calvo KR; Kaplan MJ; Colbert RA; Aksentijevich I; Young NS; Savic S; Kastner DL; Ombrello AK; Beck DB; Grayson PC
Arthritis Rheumatol; 2021 Oct; 73(10):1886-1895. PubMed ID: 33779074
[TBL] [Abstract][Full Text] [Related]
44. Further characterization of clinical and laboratory features in VEXAS syndrome: large-scale analysis of a multicentre case series of 116 French patients.
Georgin-Lavialle S; Terrier B; Guedon AF; Heiblig M; Comont T; Lazaro E; Lacombe V; Terriou L; Ardois S; Bouaziz JD; Mathian A; Le Guenno G; Aouba A; Outh R; Meyer A; Roux-Sauvat M; Ebbo M; Zhao LP; Bigot A; Jamilloux Y; Guillotin V; Flamarion E; Henneton P; Vial G; Jachiet V; Rossignol J; Vinzio S; Weitten T; Vinit J; Deligny C; Humbert S; Samson M; Magy-Bertrand N; Moulinet T; Bourguiba R; Hanslik T; Bachmeyer C; Sebert M; Kostine M; Bienvenu B; Biscay P; Liozon E; Sailler L; Chasset F; Audemard-Verger A; Duroyon E; Sarrabay G; Borlot F; Dieval C; Cluzeau T; Marianetti P; Lobbes H; Boursier G; Gerfaud-Valentin M; Jeannel J; Servettaz A; Audia S; Larue M; Henriot B; Faucher B; Graveleau J; de Sainte Marie B; Galland J; Bouillet L; Arnaud C; Ades L; Carrat F; Hirsch P; Fenaux P; Fain O; Sujobert P; Kosmider O; Mekinian A; ;
Br J Dermatol; 2022 Mar; 186(3):564-574. PubMed ID: 34632574
[TBL] [Abstract][Full Text] [Related]
45. VEXAS syndrome: Clinical manifestations, diagnosis, and treatment.
Loeza-Uribe MP; Hinojosa-Azaola A; Sánchez-Hernández BE; Crispín JC; Apodaca-Chávez E; Ferrada MA; Martín-Nares E
Reumatol Clin (Engl Ed); 2024 Jan; 20(1):47-56. PubMed ID: 38160120
[TBL] [Abstract][Full Text] [Related]
46. Characteristic vacuolisation of granulocytic and erythroid precursors associated with VEXAS syndrome.
Rieu JB; El Kassir A; Largeaud L; Dion J; Comont T; Mansat-De Mas V
Br J Haematol; 2021 Jul; 194(1):8. PubMed ID: 33651376
[No Abstract] [Full Text] [Related]
47. Case Report: VEXAS Syndrome: From Mild Symptoms to Life-Threatening Macrophage Activation Syndrome.
Staels F; Betrains A; Woei-A-Jin FJSH; Boeckx N; Beckers M; Bervoets A; Willemsen M; Neerinckx B; Humblet-Baron S; Blockmans DE; Vanderschueren S; Schrijvers R
Front Immunol; 2021; 12():678927. PubMed ID: 34046042
[TBL] [Abstract][Full Text] [Related]
48. Venous and arterial thrombosis in patients with VEXAS syndrome.
Kusne Y; Ghorbanzadeh A; Dulau-Florea A; Shalhoub R; Alcedo PE; Nghiem K; Ferrada MA; Hines A; Quinn KA; Panicker SR; Ombrello AK; Reichard K; Darden I; Goodspeed W; Durrani J; Wilson L; Olteanu H; Lasho T; Kastner DL; Warrington KJ; Mangaonkar A; Go RS; Braylan RC; Beck DB; Patnaik MM; Young NS; Calvo KR; Casanegra AI; Grayson PC; Koster MJ; Wu CO; Kanthi Y; Patel BA; Houghton DE; Groarke EM
Blood; 2024 May; 143(21):2190-2200. PubMed ID: 38306657
[TBL] [Abstract][Full Text] [Related]
49. [VEXAS syndrome : when do we have to consider it ?].
Coattrenec Y; De Lorenzi C; Samii K; Serratrice J; Seebach JD
Rev Med Suisse; 2022 Apr; 18(776):652-659. PubMed ID: 35385616
[TBL] [Abstract][Full Text] [Related]
50. VEXAS Syndrome: A Novelty in MDS Landscape.
Templé M; Kosmider O
Diagnostics (Basel); 2022 Jun; 12(7):. PubMed ID: 35885496
[TBL] [Abstract][Full Text] [Related]
51. VEXAS: is it time to reshape the nosology of clonal hematopoiesis?
Sujobert P; Largeaud L; Jamilloux Y; Heiblig M; Kosmider O
Expert Rev Hematol; 2023; 16(7):495-499. PubMed ID: 37119011
[TBL] [Abstract][Full Text] [Related]
52. UBA1 Variations in Neutrophilic Dermatosis Skin Lesions of Patients With VEXAS Syndrome.
Zakine E; Schell B; Battistella M; Vignon-Pennamen MD; Chasset F; Mahévas T; Cordoliani F; Adès L; Sébert M; Delaleu J; Jachiet M; Lepelletier C; Lemaire P; Chauvel C; Dhouaieb B; Kim R; Cassius C; Georgin-Lavialle S; Mekinian A; Bagot M; Braun T; Rousset L; Begon E; de Masson A; Fenaux P; Clappier E; Bouaziz JD
JAMA Dermatol; 2021 Nov; 157(11):1349-1354. PubMed ID: 34495287
[TBL] [Abstract][Full Text] [Related]
53. VEXAS within the spectrum of rheumatologic disease.
Koster MJ; Warrington KJ
Semin Hematol; 2021 Oct; 58(4):218-225. PubMed ID: 34802543
[TBL] [Abstract][Full Text] [Related]
54. RF - VEXAS Syndrome: A New Autoinflammatory Disease.
Fernández-Parrado M; Perandones-González H
Actas Dermosifiliogr; 2023 Jun; 114(6):531-532. PubMed ID: 36572144
[No Abstract] [Full Text] [Related]
55. VEXAS syndrome: lessons learnt from an early Australian case series.
Islam S; Cullen T; Sumpton D; Damodaran A; Heath D; Bosco A; Doo NW; Kidson-Gerber G; Cheong A; Lawford R; Walsh R; Sammel A
Intern Med J; 2022 Apr; 52(4):658-662. PubMed ID: 35419965
[TBL] [Abstract][Full Text] [Related]
56. [VEXAS syndrome - a new and common autoinflammatory disease].
Thürmel K
MMW Fortschr Med; 2024 Feb; 166(Suppl 1):28-30. PubMed ID: 38376679
[No Abstract] [Full Text] [Related]
57. VEXAS syndrome: A dermatological perspective.
Nguyen JK; Routledge D; van Der Weyden C; Blombery P; Angel CM; Johnson D; Goh MS; Lee A
Australas J Dermatol; 2022 Nov; 63(4):488-492. PubMed ID: 36197697
[TBL] [Abstract][Full Text] [Related]
58. Behçet's disease with a somatic UBA1 variant:Expanding spectrum of autoinflammatory phenotypes of VEXAS syndrome.
Matsumoto H; Asano T; Tsuchida N; Maeda A; Yoshida S; Yokose K; Fujita Y; Temmoku J; Matsuoka N; Yashiro-Furuya M; Sato S; Irie K; Norikawa N; Yamamoto T; Endo M; Fukuchi K; Ohkawara H; Ikezoe T; Uchiyama Y; Kirino Y; Matsumoto N; Watanabe H; Migita K
Clin Immunol; 2022 May; 238():108996. PubMed ID: 35398520
[No Abstract] [Full Text] [Related]
59. [Two cases of VEXAS syndrome].
Gunnarsson K; Vivar Pomiano N; Tesi B; Tobiasson M; Creignou M; Ungerstedt J
Lakartidningen; 2022 Sep; 119():. PubMed ID: 36082915
[TBL] [Abstract][Full Text] [Related]
60. Extensive Multiple Organ Involvement in VEXAS Syndrome.
Takahashi N; Takeichi T; Nishida T; Sato J; Takahashi Y; Yamamura M; Ogi T; Akiyama M
Arthritis Rheumatol; 2021 Oct; 73(10):1896-1897. PubMed ID: 33881233
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
